Heat Shock Protein 90 (Hsp90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo
نویسندگان
چکیده
Heat Shock Protein 90 (Hsp90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo Bonnie Tillotson*, Kelly Slocum, John Coco, Nigel Whitebread, Brian Thomas, Kip A. West, John MacDougall, Jie Ge, Janid Ali, Vito J. Palombella, Emmanuel Normant, Julian Adams and Christian C. Fritz Infinity Pharmaceuticals, 780 Memorial Drive, Cambridge, Massachusetts, 02139 *Address correspondence to: Bonnie Tillotson, Infinity Pharmaceuticals, 780 Memorial Drive, Cambridge, Massachusetts, 02139. Tel: 1-617-453-1197, Fax: 1-617-682-1415; E-mail: [email protected]
منابع مشابه
Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo*
Several Hsp90 (heat shock protein 90) inhibitors are currently under clinical evaluation as anticancer agents. However, the correlation between the duration and magnitude of Hsp90 inhibition and the downstream effects on client protein degradation and cancer cell growth inhibition has not been thoroughly investigated. To investigate the relationship between Hsp90 inhibition and cellular effects...
متن کاملPreclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor
4-Amino substituted resorcino-isoxazole (SST0116CL1) (property of Sigma-Tau Research Switzerland S.A.) is a potent, second generation, small-molecule heat shock protein 90 inhibitor (Hsp90i). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein degradation and tumor growth inhibition. The aim of the study was to asses...
متن کاملNew molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
PURPOSE The heat shock protein 90 (Hsp90) plays an important role in chaperoning oncogenic client proteins in multiple myeloma (MM) cells, and several Hsp90 inhibitors have shown antitumor activities both in vitro and in vivo. However the precise mechanism of action of Hsp90 inhibitor in MM has not been fully elucidated. EXPERIMENTAL DESIGN We evaluated the antitumor activities of KW-2478, a ...
متن کاملY‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
Heat shock protein 90 (Hsp90) stabilizes a variety of proteins required for cancer cell survival and has been identified as a promising drug target for cancer treatment. To date, several Hsp90 inhibitors have entered into clinical trials, but none has been approved for cancer therapy yet. Thus, exploring new Hsp90 inhibitors with novel mechanisms of action is urgent. In the present study, we sh...
متن کاملPotent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
Heat shock protein 90 (Hsp90) is a molecular chaperone that promotes the conformational maturation of numerous client proteins, many of which play critical roles in tumor cell growth and survival. The ansamycin-based Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) is currently in phase I/II clinical testing. However, 17-AAG is difficult to formulate and displays weak activity ag...
متن کامل